EXoPERT Joins Johnson & Johnson’s JLABS TMC to Advance AI Cancer Diagnostics
EXoPERT has joined JLABS TMC, part of Johnson & Johnson’s global incubator network, announced in a press release. The Houston-based biotechnology company develops AI-powered exosome-based liquid biopsy diagnostics for early cancer detection.
As a JLABS resident, EXoPERT gains access to infrastructure, resources, and partnerships across the pharmaceutical, biotechnology, and medical technology sectors. The company aims to advance clinical validation of its platform, which integrates high-purity exosome isolation, surface-enhanced Raman spectroscopy, and AI-driven molecular analysis to enable non-invasive detection of early-stage cancers.
EXoPERT is collaborating with institutions including Johns Hopkins University School of Medicine, City of Hope, and several U.S. Department of Veterans Affairs medical centers. These partnerships will support evaluation of the platform’s performance across diverse patient populations and assist in moving toward regulatory approval.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more